Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib

被引：0
|
作者：
Liam, C. K. [1 ]
Kim, T. M. [2 ,3 ]
Yang, J-J. [4 ,5 ]
Huang, C. [6 ]
Voon, P-J. [7 ]
Tho, L. M. [8 ]
Zhou, Q. [9 ]
Wang, J. [10 ]
Hayashi, H. [11 ]
Tan, D. S. W. [12 ]
Danchaivijitr, P. [13 ]
Nguyen, V. N. [14 ]
Wong, K. H. [15 ]
Yang, J. C-H. [16 ]
Le, X. [17 ]
Ellers-Lenz, B. [18 ]
Karachaliou, N. [19 ]
Ghori, V. [20 ]
Berghoff, K. [20 ]
Wu, Y-L. [5 ,21 ]
机构：
[1] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[2] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[4] Guangdong General Hosp, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China
[5] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Fujian Canc Hosp, Dept Thorac Oncol, Fujian, Peoples R China
[7] Hosp Umum Sarawak, Sarawak, Malaysia
[8] Pantai Hosp Kuala Lumpur, Dept Oncol, Kuala Lumpur, Malaysia
[9] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China
[10] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China
[11] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[12] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[13] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Internal Med,Div Med Oncol, Bangkok, Thailand
[14] Natl Lung Hosp, Hanoi, Vietnam
[15] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[16] Natl Taiwan Univ, Canc Ctr, Dept Med Oncol, Taipei, Taiwan
[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[18] Merck Healthcare KGaA, Dept Biostat, Darmstadt, Germany
[19] Merck Healthcare KGaA, Global Clin Dev, Darmstadt, Germany
[20] Merck Healthcare KGaA, Global Patient Safety, Darmstadt, Germany
[21] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
566P
引用
收藏
页码：S1691 / S1691
页数：1
相关论文
共 50 条
  • [31] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
    Ahn, M.
    Cantarini, M.
    Frewer, P.
    Hawkins, G.
    Peters, J.
    Howarth, P.
    Ahmed, G.
    Sahota, T.
    Hartmaier, R.
    Li-Sucholeiki, X.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
  • [32] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [33] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [34] The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
    Chen, Kuan-Chih
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    ONCOTARGETS AND THERAPY, 2023, 16 : 317 - 326
  • [35] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
  • [36] Tepotinib plus Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT
    OHara, R.
    Liam, C. Kin
    Ahmad, A. Rozila
    Hsia, T. -C.
    Zhou, J.
    Kim, D. -W.
    Soo, R. Andrew
    Cheng, Y.
    Lu, S.
    Shin, S. Won
    Yang, J. Chih-Hsin
    Zhang, Y.
    Zhao, J.
    Bruns, R.
    Johne, A.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E6 - E7
  • [37] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification (METamp): final analysis of INSIGHT
    Liam, Chong Kim
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 177 - 177
  • [38] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [39] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [40] Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
    Nguyen, D.
    Besse, B.
    Cho, B. C.
    Lee, S. -H.
    Lee, K. H.
    Lu, S.
    Cheng, Y.
    Yao, Y.
    Girard, N.
    Lin, C. -C.
    Felip, E.
    Aguilar, A.
    Charoentum, C.
    Cruz, F. J. S. M.
    Majem, M.
    Lim, C. S.
    Akamatsu, H.
    Hayashi, H.
    Yang, J. C. -H.
    Kowalyszyn, R.
    Tiscoski, K.
    Franke, F.
    Ponomarenko, D.
    Arslan, C.
    Forster, M.
    Urban, D.
    Misch, D.
    Delmonte, A.
    Montes, L. V. G.
    Gadgeel, S. M.
    Cruz-Correa, M.
    Peguero, J.
    Rousey, S.
    Gaffar, Y.
    Owen, S.
    Schuchard, J.
    Diels, J.
    Sermon, J.
    Sun, T.
    Ennis, M.
    Fennema, E.
    Daksh, M.
    Sethi, S.
    Bauml, J. M.
    Garcia Campelo, M. R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S103 - S104
12345